Introduction & Objective: Diabetes is a chronic disease associated with many comorbidities and a higher risk of all-cause and cardiovascular mortality. The GLEEN Study is a previously reported double-blind randomised placebo-controlled trial that evaluated the efficacy and safety of daily GlucoLo Plus, a Complementary and Alternative Medicine (CAM). The secondary outcome of lipid profile improvement will now be presented.

Methods: The GLEEN Study was composed of 60 individuals with type 2 diabetes with a mean HbA1c 6.98% [52.8 mmol/mol], mean age 67.3 years [SD 9.5], 26 [43%] women, mean diabetes duration was 3.2 years, and meanbody mass index 27.9 kg/m2. Participants were randomly assigned to GlucoLo Plus (n=32 [53%]), or placebo (n=28 [47%]). The primary outcome of a significant HbA1c reduction of 0.843% was previously reported. The lipid profile including Total Cholesterol, Triglycerides, High-Density Lipoprotein (HDL) and Low-Density Lipoprotein (LDL) were measured at randomization and at the end of the 3-month trial.

Results: At 12 weeks, GlucoLo Plus decreased Total Cholesterol by 4.47 % while placebo increased it by 0.62%. The active arm had a decrease in Triglycerides by 10.33 % while the placebo arm had a Triglycerides lowering of 12.44%. GlucoLo Plus further improved the lipid profile by reducing LDL by 7.45 % while placebo increased it by 2.70% and it increased HDL by 14.52% while placebo reduced it by 0.38%.

Conclusion: GlucoLo Plus showed favorable effect regarding lowering Total Cholesterol, lowering LDL cholesterol and increasing HDL cholesterol. These results suggest that GlucoLo Plus could be, in addition to its’s proven glucose lowering abilities, an alternative and/or an addition to type 2 diabetes management in people who are reluctant to initiate or add new antidiabetic agents while providing them with some lipid profile benefits at the same time.

Disclosure

A.R. Zarruk: Consultant; Sanofi. Speaker's Bureau; Sanofi. Consultant; Bausch Health. Speaker's Bureau; Bausch Health. Consultant; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Consultant; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim, Abbott. Consultant; Abbott.

Funding

Groupe Nature Pharma

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.